secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001437749-24-024718
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.2, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness
--------------------------------------------------------------------------------

- Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.
- Raises FY 2024 BRIUMVI revenue target to ~$290-300M, up from $270-290M.
- New $250M term loan repays $107M Hercules debt; $100M share repurchase authorized.
- Material weakness in ICFR from 2021 restricted stock grant error; immaterial to financials; 10-K/A to be filed.
- Phase 1 subcutaneous ublituximab in RMS initiated; FDA IND clearance for azer-cel in progressive MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/0001437749-24-024718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924024718/tgtx20240805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-024718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer